Genetic and epigenetic alterations of VHL gene in clear cell renal cell carcinoma

  • K. V. Onyshchenko
  • V. M. Grygorenko
  • L. V. Pereta
  • Yu. R. Serbai
  • T. V. Voitsitskyi
  • I. Ya. Skrypkina
DOI: https://doi.org/10.7124/FEEO.v24.1105

Abstract

Aim. Renal cell carcinomas (RCC) – cancerous neoplasms of the genitourinary system representing about 3% of human malignant tumors. For malignancy degree indexing and tumor typing, shape of cell nucleus is widely used. However, genetic changes, in particular inactivation of von Hippel-Lindau (VHL) gene can serve as indicators of RCC progression. Thus, the purpose of our study was establishing the methylation status and loss of heterozygosity of the VHL gene as a potential and applicable clinical marker of kidney tumors. Methods. Determination of allelic imbalance in VHL gene expression was performed by PCR of STR-markers with subsequent fragments separation in 8% PAAG and by capillary gel electrophoresis of fluorescent-labeled PCR fragments. Methyl-specific PCR was used for epigenetic variability of VHL gene promoter. To detect statistically significant differences between tumor specimens and adjacent kidney tissues, Fisher's exact test and Mann-Whitney U-criterion were applied. Results. In 57% of the tumor samples for the marker D3S1038 and 48% for the D3S1317 loss of heterozygosity of the VHL gene was detected. Polymorphic information content for these loci was 84% for D3S1038 and 90% for D3S1317. The VHL promoter hypermethylation was 77%. Conclusions. The obtained results indicate that VHL gene can be reviewed as a candidate for not only diagnostic, but also prognostic application in RCC cancer.

Keywords: clear cell renal cell carcinoma, epigenetic changes, methylation, loss of heterozygosity, VHL.

References

Belldegrum A., deKernion J.B. Renal tumors / In: Walsh P.C., Retik A.B., Vaughan E.D.Jr, Wein A.J., editors. Campbell’s urology. 7thed. Philadelphia (PA): W.B. Saunders Company. 1998. P. 2283–22326.

Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treatment Reviews. 2008. Vol. 34. P. 193–205. doi: 10.1016/j.ctrv.2007.12.001.

Virtanen I., Lehto V.P. Progression of malignancy in clear cell renal cell carcinomas. Scand J Surg. 2004. Vol. 93. P. 112–117. doi: 10.1177/145749690409300205.

Linehan W.M., Vasselli J., Srinivasan R., Walther M.M., Merino M., Choyke P., Vocke C., Schmidt L., Isaacs J.S., Glenn G., Toro J., Zbar B., Bottaro D., Neckers L. Genetic Basis of Cancer of the Kidney: Disease-Specific Approaches to Therapy. Clin. Canc. Res. 2004. Vol. 10. P. 6282–6289. doi: 10.1158/1078-0432.CCR-050013.

Gnarra J.R., Tory K. Weng Y., Schmidt L., Wei M.H., Li H. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994. Vol. 7. P. 85–90. doi: 10.1038/ng0594-85.

Shuin T., Kondo K., Torigoe S., Kishida T., Kubota Y., Hosaka M., Nagashima Y., Kitamura H., Latif F., Zbar B. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994. Vol. 54. P. 2852–2855.

Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M.. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 1994. Vol. 91. P. 9700–9704.

Brauch H., Weirich G., Brieger J., Glavac D., Rodl H., Eichinger M., Feurer M., Weidt E., Puranakanitstha C., Neuhaus C., Pomer S., Brenner W., Schirmacher P., Störkel S., Rotter M., Masera A., Gugeler N., Decker H.J. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000. Vol. 60. P. 1942–1948.

Kondo K., Yao M., Yoshida M., Kishida T., Shuin T., Miura T. et al. Com-prehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinico-pathological parameters. Genes Chromosomes Cancer. 2002. Vol. 34. P. 58–68.

Iliopoulos O., Kibel A., Gray S., Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1995. Vol. 1. P. 822–826.

Chen F., Kishida T., Duh F.M., Renbaum P., Orcutt M.L., Schmidt L., Zbar B. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 1995. Vol. 55. P. 4804–4807.

Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., Wilson G.D., Turley H., Talks K.L., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000. Vol. 60. P. 7075–7083.

Wiesener M.S., Munchenhagen P.M., Berger I., Morgan N.V., Roigas J., Schwiertz A., Jürgensen J.S., Gruber G., Maxwell P.H., Löning S.A., Frei U., Maher E.R., Gröne H.J., Eckardt K.U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 2001. Vol. 61. P. 5215–5222.

Tsuchiya H., Iseda T., Hino O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res. 1996. Vol. 56. P. 2881–2885.

Ohh M., Yauch R.L, Lonergan KM, Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin W.G.Jr, Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1998. Vol. 1. P. 959–968.

Okuda H., Hirai S., Takaki Y., Kamada M., Baba M., Sakai N., Kishida T., Kaneko S., Yao M., Ohno S., Shuin T. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem. Biophys. Re.s Commun. 1999. Vol. 263. P. 491–749. doi: 10.1006/bbrc.1999.1347.

Cohen H.T., Zhou M., Welsh A.M., Zarghamee S., Scholz H., Mukhopadhyay D., Kishida T., Zbar B., Knebelmann B., Sukhatme V.P. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem. Biophys. Res. Commun. 1999. Vol. 266. P. 43–50. doi: 10.1006/bbrc.1999.1767.

Yao M., Yoshida M., Kishida T., Nakaigawa N., Baba M., Kobayashi K., Miura T., Moriyama M., Nagashima Y., Nakatani Y., Kubota Y., Kondo K. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl. Cancer. Inst. 2002. Vol. 94. P. 1569–1575.

Druck T., Kastury K., Hadaczek P., Podolski J., Toloczko A., Sikorski A., Ohta M., LaForgia S., Lasota J., McCue P., Lubin-ski J., Huebner K. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal. Cancer Res. 1995. Vol. 55. P. 5348–5353.

Hadaczek P., Podolski J., Toloczko A., Kurzawski G., Sikorski A., Rabbitts P., Huebner K., Lubinski J. Accumulation of losses at 3p common deletion sites is characteristic of clear cell renal cell carcinoma. Virchows Arch. 1996. Vol. 429. P. 37–42.

Kim W.Y., Kaelin W.G. Role of VHL Gene Mutation in Human Cancer. Journal of clinical oncology. 2004. Vol. 22. P. 4911–5004. doi: 10.1200/JCO.2004.05.061.

Hamano K., Esumi M., Igarashi H., Chino K., Mochida J., Ishida H., Okada K. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. J Urol. 2002. Vol. 167. P. 713–717.

Cheng L., Zhang S., MacLennan G.T., Lopez-Beltran A., Montironi R. Molecular and cytogenetic insights into the pathogene-sis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum. Pathol. 2009. Vol. 40. P. 10–29. doi: 10.1016/j.humpath.2008.09.009.